You are leading a pharmaceutical project using a hybrid model where clinical trial protocols follow FDA-mandated predictive processes, while patient recruitment and engagement strategies use adaptive methods with two-week iterations. During a retrospective, the adaptive team identifies that current recruitment messaging isn't resonating with target demographics and wants to pivot their approach. However, any changes to patient-facing materials require review under the predictive compliance process, which takes four weeks. The trial needs to meet enrollment targets within three months. What is the most appropriate action?

Question

Accepted Answer

The correct answer is B. Option B is the best answer as it creates a sustainable solution that respects both the regulatory constraints of the predictive process and the need for adaptive iterations. This approach establishes guardrails within which the team can operate autonomously, enabling faster learning cycles while maintaining compliance—a key skill in hybrid project management. It aligns with Process Task 5.1 on planning and managing scope. Option C is the main distractor and maintains compliance but may result in missing enrollment targets due to ineffective messaging. Option A violates regulatory requirements and creates serious risk in a pharmaceutical context. Option D may not be feasible and doesn't address the fundamental tension between adaptive needs and compliance requirements for future iterations.

PMP Practice Question: Process — Hybrid, Medium

More Process Questions